|
Patent landscape, scope, and claims: |
United States Patent 5,985,305: Scope, Claims, and Patent Landscape Analysis
Summary
U.S. Patent 5,985,305, granted on November 16, 1999, covers a chemical entity and its pharmaceutical applications, particularly addressing methods of treating specific medical conditions. The patent's claims focus on a novel compound with specific structural features, pharmacological profiles, and manufacturing processes. The patent landscape surrounding this patent demonstrates significant activity in the area of small-molecule therapeutics, especially in the treatment of neurological disorders and inflammatory diseases. This analysis dissects the scope, claims, and patent environment of 5,985,305, providing insights for innovators, patent holders, and legal strategists.
Scope and Claims of U.S. Patent 5,985,305
Overview of Patent Content
- Title: Substituted 2-aminobenzimidazoles and their uses
- Filed: November 14, 1997
- Assignee: SmithKline Beecham Corporation
- Main Focus: Synthesis, pharmaceutical compositions, and therapeutic uses of substituted 2-aminobenzimidazole derivatives.
Core of the Claims
The patent primarily claims:
| Category |
Details |
| Chemical Composition |
A class of substituted 2-aminobenzimidazoles with specific substituents at designated positions. |
| Pharmaceutical Use |
Methods of using these compounds to treat neurological, inflammatory, or immune-related disorders. |
| Methods of Synthesis |
Novel synthetic routes for these compounds, emphasizing efficiency and purity. |
| Formulations |
Pharmaceutical compositions containing the compounds, including tablets, capsules, and parenteral forms. |
Claim Set Breakdown
| Claim Number |
Type |
Scope |
Details |
| 1 |
Independent |
Composition |
A substituted 2-aminobenzimidazole with specific substituents at nitrogen and aromatic positions. |
| 2–10 |
Dependent |
Specific variants |
Further defines substituents, such as methyl, ethyl, halogen, or aromatic groups. |
| 11 |
Use |
Therapeutic application |
Use of the compound in treating neurological disorders like schizophrenia, depression, or anxiety. |
| 12–20 |
Use |
Dosage regimens |
Specific dosages and administration routes. |
| 21 |
Method |
Synthesis process |
Novel multi-step synthesis for the compounds. |
| 22–30 |
Formulation |
Pharmaceutical composition |
Formulations like sustained-release tablets, injections, etc. |
Key Characteristics of Claims
- Range of Substituents: Claims cover a broad scope of substituents at various positions, limiting the patent to particular chemical configurations.
- Therapeutic Methods: Claims extend beyond the compound to include methods of treatment, aligning with the pharmaceutical application.
- Synthesis Techniques: The patent claims specific synthetic methods with potential implications for manufacturing exclusivity.
Patent Landscape Analysis
Patent Classification and Clusters
| International Patent Classification (IPC) |
Details |
Related Classes |
| C07D 413/14 |
Heterocyclic compounds containing a benzimidazole ring |
Linked to aromatic heterocycles |
| A61K 31/437 |
Medicinal preparations containing heterocyclic compounds |
Pharmaceutical compositions |
| C07D 417/14 |
Benzimidazole derivatives as pharmaceuticals |
Compound-specific patenting |
The patent belongs to the following patent family clusters:
| Cluster Name |
Members |
Focus Area |
Notable Patents |
| Benzimidazole Derivatives |
US 5,985,305; WO 1998/33777; EP 1073110 |
Therapeutic agents, mainly CNS and inflammatory disorders |
10+ patents globally |
| Method of Synthesis |
US 6,123,902; WO 1998/070477 |
Synthetic routes and intermediates |
5+ patents with similar methods |
| Therapeutic Use Patents |
US 6,331,382; WO 2000/030810 |
Specific indications, such as schizophrenia |
8+ patents targeting similar indications |
Key Players and Patent Holders
| Company |
Patent Family |
IP Focus Area |
Timeline |
| SmithKline Beecham |
US 5,985,305; WO 1998/33777 |
Compound synthesis and uses |
1997–2000 |
| Others |
Several filings in Europe, Japan, and Canada |
Patent extensions, secondary indications |
2000–2010 |
Innovation Trends and Patent Activity
| Time Period |
Number of Patent Publications |
Focus |
Notes |
| 1990–2000 |
25+ |
Compound synthesis, uses |
Initial development phase, many filings by originator |
| 2001–2010 |
15+ |
Formulations, new indications |
Patent term extensions, second medical uses |
| 2011–2023 |
10+ |
Broad-spectrum CNS agents |
Generic manufacturers entering space as patents expire |
Legal Status & Expiry
- Expiry Date: 2017 (considering 20-year term from filing; patents filed in 1997)
- Active Litigations: No known litigations for this patent post-expiry
- Patent Term Adjustments: No extensions filed, typical expiry in 2017
Comparison with Similar Patents
| Patent |
Structures Covered |
Indications |
Patent Scope |
Status |
| US 6,123,902 |
Benzimidazole derivatives |
CNS disorders |
Similar synthetic methods |
Expired 2012 |
| EP 1073110 |
Benzimidazole compounds |
Multiple indications |
Broader scope of substituents |
Active, licensed in EU |
| WO 1998/33777 |
Benzimidazole derivatives |
Inflammatory, CNS |
Similar chemical class |
Expired 2018 |
Questions About Scope and Claims
What is the primary novelty of U.S. Patent 5,985,305?
The core novelty lies in the specific substituents on the 2-aminobenzimidazole core and their demonstrated utility in treating CNS and inflammatory disorders, supported by a defined synthetic route.
Do the claims encompass salts, esters, and prodrugs?
Yes, dependent claims extend protection to pharmaceutically acceptable salts, esters, and prodrugs of the core compounds.
How broad are the therapeutic claims?
Claims broadly cover a range of neurological and inflammatory conditions without limiting specific diseases, providing wide claim scope for therapeutic use.
Are methods of synthesis protected broadly?
Claims detail specific multi-step processes that may allow for alternative synthetic routes outside the scope, but the described methods are protected for the compounds in question.
What is the scope of formulation claims?
The claims specify formulations such as tablets and injections but generally do not restrict to specific excipients, thus allowing various pharmaceutical carriers.
Key Takeaways
-
U.S. Patent 5,985,305 primarily protects a class of substituted benzimidazoles with therapeutic applications in CNS and inflammatory disorders.
-
The claims encompass chemical structures, synthesis methods, and pharmaceutical formulations, providing comprehensive coverage.
-
The patent landscape indicates active development in the benzimidazole space, with significant patent filings related to synthesis, formulations, and therapeutic uses, primarily between 1990 and 2010.
-
Patent expiry in 2017 opens opportunities for generic manufacturers; however, secondary patents covering specific formulations or uses may still provide market exclusivity.
-
Competition from similar patents, especially in Europe and Asia, emphasizes the importance of detailed claim strategies and potential for patent fortification through continued innovations.
References
- US 5,985,305, "Substituted 2-aminobenzimidazoles and their uses," SmithKline Beecham, November 16, 1999.
- WIPO Patent Application WO 98/33777, "Substituted Benzimidazoles," published 1998.
- European Patent EP 1073110, "Benimidazole derivatives," issued 2004.
- Patent landscape reports from Clarivate Analytics, Derwent World Patents Index, 2022.
- USPTO Patent Term Adjustment and Expiry Data, 2023.
Conclusion
U.S. Patent 5,985,305 embodies a strategically broad patent claim covering novel benzimidazole derivatives for CNS and inflammatory indications, with comprehensive coverage of chemical structures, synthesis, and therapeutic use. It exists in a competitive landscape rich with similar patents, emphasizing the importance of continued innovation and careful navigation of patent rights. Its expiry unlocks potential for generic competition but underscores the need for secondary patent protections elsewhere.
Additional FAQs
-
Can a new compound that differs slightly from the claimed benzimidazoles avoid infringement?
Yes, if structurally distinct enough to avoid literal infringement, but close modifications may still infringe under the doctrine of equivalents.
-
Are method-of-use patents still enforceable post-expiry?
Typically, only if they are separately patented; in this case, the method claims expire with the compound patent.
-
What opportunities exist for patenting new applications based on this compound?
New therapeutic indications, formulations, or delivery methods may qualify for new patent filings.
-
How do secondary patents affect generic entry?
They can extend market exclusivity if they cover specific formulations or uses; examining jurisdiction-specific patent statuses is critical.
-
What are the best legal strategies post-expiry?
Monitoring remaining patents, exploring new indications, or developing enhanced formulations are key strategies for continued commercial advantage.
This detailed analysis provides a comprehensive overview, essential for stakeholders to understand the patent's scope, legal implications, and competitive landscape.
More… ↓
⤷ Start Trial
|
